Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
14
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Looker Benjamin | General Counsel | 2 | $0 | $0 | 2021-11-17 |
| Uger Robert | Chief Scientific Officer | 44 | $0 | $495.9K | 2021-11-17 |
| Harrison Rosemary | See Remarks | 2 | $0 | $0 | 2021-11-17 |
| Petrova Penka | Chief Development Officer | 32 | $0 | $280.1K | 2021-11-17 |
| Skvarka Jan | President and CEO | 17 | $0 | $1.58M | 2021-11-17 |
| Bruns Ingmar | Chief Medical Officer | 1 | $0 | $0 | 2021-11-17 |
| Parsons James T. | Chief Financial Officer | 11 | $0 | $134.3K | 2021-11-17 |
| TAYTON-MARTIN HELEN KATRINA | Director | 2 | $0 | $0 | 2021-11-17 |
| MACKEY CATHERINE J | Director | 2 | $0 | $0 | 2021-11-17 |
| Walker Paul Edward | Director | 5 | $0 | $0 | 2021-11-17 |
| Kamarck Michael E. | Director | 1 | $0 | $0 | 2021-11-17 |
| Pucci Paolo | Director | 1 | $0 | $0 | 2021-11-17 |
| Myers Scott Dunseth | Director | 2 | $0 | $0 | 2021-11-17 |
| BESHAR LUKE M | Director | 3 | $0 | $0 | 2021-11-17 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Skvarka Jan | President and CEO | D To issuer deriv | 2021-11-17 | 2021-11-19 | 600,000 | — | $0 | 0 | SEC↗ |
| Skvarka Jan | President and CEO | D To issuer deriv | 2021-11-17 | 2021-11-19 | 1,162,500 | — | $0 | 0 | SEC↗ |
| Skvarka Jan | President and CEO | D To issuer deriv | 2021-11-17 | 2021-11-19 | 197,000 | — | $0 | 0 | SEC↗ |
| TAYTON-MARTIN HELEN KATRINA | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 498,294 | — | $0 | 0 | SEC↗ |
| TAYTON-MARTIN HELEN KATRINA | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 40,000 | — | $0 | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 102,083 | — | $0 | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 58,333 | — | $0 | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 5,260 | — | $0 | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 23,473 | — | $0 | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 29,073 | — | $0 | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 250,000 | — | $0 | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 38,808 | — | $0 | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 4,574 | — | $0 | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 49,480 | — | $0 | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 83,960 | — | $0 | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 140,000 | — | $0 | 0 | SEC↗ |
| Bruns Ingmar | Chief Medical Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 400,000 | — | $0 | 0 | SEC↗ |
| MACKEY CATHERINE J | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 67,000 | — | $0 | 0 | SEC↗ |
| Looker Benjamin | General Counsel | D To issuer deriv | 2021-11-17 | 2021-11-19 | 190,000 | — | $0 | 0 | SEC↗ |
| Kamarck Michael E. | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 67,000 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 94,792 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 180,000 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 59,896 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 5,761 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 36,204 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 24,390 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 30,171 | — | $0 | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | D To issuer deriv | 2021-11-17 | 2021-11-19 | 30,171 | — | $0 | 0 | SEC↗ |
| BESHAR LUKE M | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 6,666 | — | $0 | 0 | SEC↗ |
| BESHAR LUKE M | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 547,656 | — | $0 | 0 | SEC↗ |
| BESHAR LUKE M | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 40,000 | — | $0 | 0 | SEC↗ |
| Harrison Rosemary | See Remarks | D To issuer deriv | 2021-11-17 | 2021-11-19 | 180,000 | — | $0 | 0 | SEC↗ |
| Myers Scott Dunseth | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 67,000 | — | $0 | 0 | SEC↗ |
| Pucci Paolo | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 67,000 | — | $0 | 0 | SEC↗ |
| Walker Paul Edward | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 40,000 | — | $0 | 0 | SEC↗ |
| Walker Paul Edward | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 850,000 | — | $0 | 0 | SEC↗ |
| Walker Paul Edward | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 6,750,000 | — | $0 | 0 | SEC↗ |
| Walker Paul Edward | Director | D To issuer deriv | 2021-11-17 | 2021-11-19 | 5,400,000 | — | $0 | 0 | SEC↗ |
| Harrison Rosemary | See Remarks | D To issuer | 2021-11-17 | 2021-11-19 | 75 | — | $0 | 0 | SEC↗ |
| Walker Paul Edward | Director | D To issuer | 2021-11-17 | 2021-11-19 | 5,736,363 | — | $0 | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-07-07 | 2021-07-09 | 3,646 | — | $0 | 102,083 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-07-07 | 2021-07-09 | 3,646 | $0.30 | $1.1K | 3,646 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-07-07 | 2021-07-09 | 3,646 | $9.00 | $32.8K | 0 | SEC↗ |
| MACKEY CATHERINE J | Director | A Award deriv | 2021-07-01 | 2021-07-02 | 67,000 | — | $0 | 67,000 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-06-07 | 2021-06-09 | 3,646 | — | $0 | 105,729 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-06-07 | 2021-06-09 | 3,646 | $8.27 | $30.2K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-06-07 | 2021-06-09 | 3,646 | $0.32 | $1.2K | 3,646 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise deriv | 2021-05-12 | 2021-05-13 | 23,802 | — | $0 | 197,000 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise | 2021-05-12 | 2021-05-13 | 23,802 | $0.31 | $7.4K | 23,802 | SEC↗ |
| Skvarka Jan | President and CEO | S Sale | 2021-05-12 | 2021-05-13 | 23,802 | $9.24 | $219.9K | 0 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise deriv | 2021-05-11 | 2021-05-13 | 19,198 | — | $0 | 220,802 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise deriv | 2021-05-11 | 2021-05-13 | 87,500 | — | $0 | 1,162,500 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise | 2021-05-11 | 2021-05-13 | 87,500 | $0.45 | $39.4K | 87,500 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise | 2021-05-11 | 2021-05-13 | 19,198 | $0.31 | $6.0K | 106,698 | SEC↗ |
| Skvarka Jan | President and CEO | S Sale | 2021-05-11 | 2021-05-13 | 106,698 | $9.20 | $981.6K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-05-07 | 2021-05-11 | 3,646 | — | $0 | 109,375 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-05-07 | 2021-05-11 | 3,646 | $0.31 | $1.1K | 3,646 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-05-07 | 2021-05-11 | 3,646 | $9.30 | $33.9K | 0 | SEC↗ |
| Myers Scott Dunseth | Director | A Award deriv | 2021-05-03 | 2021-05-05 | 67,000 | — | $0 | 67,000 | SEC↗ |
| Looker Benjamin | General Counsel | A Award deriv | 2021-05-03 | 2021-05-05 | 190,000 | — | $0 | 190,000 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-04-08 | 2021-04-09 | 2,708 | — | $0 | 83,960 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-04-08 | 2021-04-09 | 2,604 | — | $0 | 49,480 | SEC↗ |
| Petrova Penka | Chief Development Officer | S Sale | 2021-04-08 | 2021-04-09 | 5,312 | $11.09 | $58.9K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-04-08 | 2021-04-09 | 2,604 | $3.36 | $8.7K | 5,312 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-04-08 | 2021-04-09 | 2,708 | $0.30 | $812 | 2,708 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-04-07 | 2021-04-09 | 3,646 | — | $0 | 113,021 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-04-07 | 2021-04-09 | 3,646 | $0.30 | $1.1K | 3,646 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-04-07 | 2021-04-09 | 3,646 | $10.82 | $39.4K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-03-12 | 2021-03-15 | 2,917 | — | $0 | 58,333 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-03-12 | 2021-03-15 | 2,917 | $3.39 | $9.9K | 2,917 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-03-12 | 2021-03-15 | 2,917 | $11.97 | $34.9K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-03-10 | 2021-03-12 | 2,604 | — | $0 | 52,084 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-03-10 | 2021-03-12 | 2,708 | — | $0 | 86,668 | SEC↗ |
| Petrova Penka | Chief Development Officer | S Sale | 2021-03-10 | 2021-03-12 | 5,312 | $11.08 | $58.9K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-03-10 | 2021-03-12 | 2,604 | $3.35 | $8.7K | 5,312 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-03-10 | 2021-03-12 | 2,708 | $0.30 | $812 | 2,708 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-03-08 | 2021-03-10 | 3,646 | — | $0 | 116,667 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-03-08 | 2021-03-10 | 3,646 | $0.30 | $1.1K | 3,646 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-03-08 | 2021-03-10 | 3,646 | $10.11 | $36.9K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-02-09 | 2021-02-10 | 584 | — | $0 | 5,260 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-02-09 | 2021-02-10 | 508 | — | $0 | 4,574 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-02-09 | 2021-02-10 | 584 | $9.62 | $5.6K | 584 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-02-09 | 2021-02-10 | 584 | $14.12 | $8.2K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | S Sale | 2021-02-09 | 2021-02-10 | 508 | $14.17 | $7.2K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-02-09 | 2021-02-10 | 508 | $9.62 | $4.9K | 508 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-02-08 | 2021-02-10 | 2,917 | — | $0 | 61,250 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-02-08 | 2021-02-10 | 3,646 | — | $0 | 120,313 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-02-08 | 2021-02-10 | 2,708 | — | $0 | 89,376 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-02-08 | 2021-02-10 | 2,604 | — | $0 | 54,688 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-02-08 | 2021-02-10 | 6,563 | $12.65 | $83.0K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-02-08 | 2021-02-10 | 2,917 | $3.31 | $9.7K | 6,563 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-02-08 | 2021-02-10 | 3,646 | $0.30 | $1.1K | 3,646 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-02-08 | 2021-02-10 | 2,708 | $0.30 | $812 | 2,708 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-02-08 | 2021-02-10 | 2,604 | $3.31 | $8.6K | 5,312 | SEC↗ |
| Petrova Penka | Chief Development Officer | S Sale | 2021-02-08 | 2021-02-10 | 5,312 | $12.65 | $67.2K | 0 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise deriv | 2021-01-14 | 2021-01-15 | 19,581 | — | $0 | 1,250,000 | SEC↗ |
| Skvarka Jan | President and CEO | S Sale | 2021-01-14 | 2021-01-15 | 19,581 | $15.03 | $294.3K | 0 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise | 2021-01-14 | 2021-01-15 | 19,581 | $0.43 | $8.4K | 19,581 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise deriv | 2021-01-13 | 2021-01-15 | 5,419 | — | $0 | 1,269,581 | SEC↗ |
| Skvarka Jan | President and CEO | M Exercise | 2021-01-13 | 2021-01-15 | 5,419 | $0.42 | $2.3K | 5,419 | SEC↗ |
| Skvarka Jan | President and CEO | S Sale | 2021-01-13 | 2021-01-15 | 5,419 | $15.04 | $81.5K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-01-11 | 2021-01-13 | 508 | — | $0 | 5,082 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-01-11 | 2021-01-13 | 584 | — | $0 | 5,844 | SEC↗ |
| Petrova Penka | Chief Development Officer | S Sale | 2021-01-11 | 2021-01-13 | 508 | $15.21 | $7.7K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-01-11 | 2021-01-13 | 508 | $9.57 | $4.9K | 508 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-01-11 | 2021-01-13 | 584 | $15.20 | $8.9K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-01-11 | 2021-01-13 | 584 | $9.57 | $5.6K | 584 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-01-08 | 2021-01-12 | 2,604 | — | $0 | 57,292 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-01-08 | 2021-01-12 | 5,600 | — | $0 | 23,473 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-01-08 | 2021-01-12 | 2,917 | — | $0 | 64,167 | SEC↗ |
| Parsons James T. | Chief Financial Officer | M Exercise deriv | 2021-01-08 | 2021-01-12 | 8,505 | — | $0 | 5,761 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-01-08 | 2021-01-12 | 2,604 | $3.33 | $8.7K | 2,604 | SEC↗ |
| Petrova Penka | Chief Development Officer | S Sale | 2021-01-08 | 2021-01-12 | 2,604 | $15.50 | $40.4K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-01-08 | 2021-01-12 | 2,917 | $3.33 | $9.7K | 2,917 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-01-08 | 2021-01-12 | 5,600 | $11.01 | $61.7K | 5,600 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-01-08 | 2021-01-12 | 2,917 | $15.51 | $45.2K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-01-08 | 2021-01-12 | 5,600 | $15.82 | $88.6K | 0 | SEC↗ |
| Parsons James T. | Chief Financial Officer | M Exercise | 2021-01-08 | 2021-01-12 | 8,505 | $7.24 | $61.6K | 8,505 | SEC↗ |
| Parsons James T. | Chief Financial Officer | S Sale | 2021-01-08 | 2021-01-12 | 8,505 | $15.79 | $134.3K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise deriv | 2021-01-07 | 2021-01-11 | 3,646 | — | $0 | 123,959 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise deriv | 2021-01-07 | 2021-01-11 | 2,708 | — | $0 | 92,084 | SEC↗ |
| Uger Robert | Chief Scientific Officer | S Sale | 2021-01-07 | 2021-01-11 | 3,646 | $14.75 | $53.8K | 0 | SEC↗ |
| Uger Robert | Chief Scientific Officer | M Exercise | 2021-01-07 | 2021-01-11 | 3,646 | $0.30 | $1.1K | 3,646 | SEC↗ |
| Petrova Penka | Chief Development Officer | S Sale | 2021-01-07 | 2021-01-11 | 2,708 | $14.71 | $39.8K | 0 | SEC↗ |
| Petrova Penka | Chief Development Officer | M Exercise | 2021-01-07 | 2021-01-11 | 2,708 | $0.30 | $812 | 2,708 | SEC↗ |